A case-control study: epigenetic age acceleration in psoriasis.
Case-control study
Epigenetic age
Psoriasis
Psoriatic arthritis
Journal
Archives of dermatological research
ISSN: 1432-069X
Titre abrégé: Arch Dermatol Res
Pays: Germany
ID NLM: 8000462
Informations de publication
Date de publication:
07 Jun 2024
07 Jun 2024
Historique:
received:
03
01
2024
accepted:
26
04
2024
revised:
25
01
2024
medline:
7
6
2024
pubmed:
7
6
2024
entrez:
7
6
2024
Statut:
epublish
Résumé
Psoriasis (PsO) is a chronic inflammatory skin condition, often accompanied by psoriatic arthritis (PsA) and linked to various comorbidities and increased mortality rates. This study aimed to explore the relationship between PsO and accelerated biological aging, specifically focusing on epigenetic DNA methylation clocks. Using a matched case-control design, 20 PsO cases were selected along with age, race, and sex-matched 20 controls without PsO from the Skin Disease Biorepository at Brown Dermatology, Inc, Providence, Rhode Island. Blood samples retrieved from both groups were analyzed for DNA methylation, and epigenetic ages were calculated using DNA methylation clocks, including Horvath, Hannum, Pheno, SkinBlood, and Grim ages. Generalized estimation equations were employed to test the differences in epigenetic and chronological ages between PsO cases and controls, as well as within various subgroups in comparison to their respective controls. There were no statistically significant differences in epigenetic ages between PsO cases and controls. However, notably, PsO cases with PsA demonstrated an accelerated PhenoAge, compared to their matched controls. This study represents a pioneering investigation into the potential link between PsO and epigenetic aging, shedding light on the possibility of accelerated epigenetic aging in PsA, possibly associated with heightened inflammatory burden. These findings emphasize the systemic impact of PsA on the aging process, prompting the need for deeper exploration into autoimmune pathways, inflammation, and epigenetic modifications underlying PsO pathogenesis and aging mechanisms. Larger-scale studies with diverse populations are imperative to discern PsO subgroups experiencing accelerated biological aging and decipher the intricate interplay between PsO, inflammation, and aging pathways.
Identifiants
pubmed: 38847964
doi: 10.1007/s00403-024-03075-0
pii: 10.1007/s00403-024-03075-0
doi:
Types de publication
Journal Article
Letter
Langues
eng
Sous-ensembles de citation
IM
Pagination
340Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Tran MM, Moseley IH, George EA, Qureshi AA, Cho E (2023) Examining the burden of psoriasis and psoriatic arthritis in a US adult cohort using the all of us research program. J Am Acad Dermatol 89:859–862. https://doi.org/10.1016/j.jaad.2023.06.028
doi: 10.1016/j.jaad.2023.06.028
pubmed: 37356625
Ryan C, Kirby B (2015) Psoriasis is a systemic disease with multiple cardiovascular and metabolic comorbidities. Dermatol Clin 33:41–55. https://doi.org/10.1016/j.det.2014.09.004
doi: 10.1016/j.det.2014.09.004
pubmed: 25412782
Dhana A, Yen H, Yen H, Cho E (2019) All-cause and cause-specific mortality in psoriasis: a systematic review and meta-analysis. J Am Acad Dermatol 80:1332–1343. https://doi.org/10.1016/j.jaad.2018.12.037
doi: 10.1016/j.jaad.2018.12.037
pubmed: 30590074
Noe MH, Shin DB, Wan MT, Gelfand JM (2018) Objective measures of psoriasis severity predict mortality: a prospective population-based cohort study. J Invest Dermatol 138:228–230. https://doi.org/10.1016/j.jid.2017.07.841
doi: 10.1016/j.jid.2017.07.841
pubmed: 28843488
Horvath S, Raj K (2018) DNA methylation-based biomarkers and the epigenetic clock theory of ageing. Nat Rev Genet 19:371–384. https://doi.org/10.1038/s41576-018-0004-3
doi: 10.1038/s41576-018-0004-3
pubmed: 29643443
Oblak L, van der Zaag J, Higgins-Chen AT, Levine ME, Boks M (2021) P. A systematic review of biological, social and environmental factors associated with epigenetic clock acceleration. Ageing Res Rev 69:101348. https://doi.org/10.1016/j.arr.2021.101348
doi: 10.1016/j.arr.2021.101348
pubmed: 33930583
Nwanaji-Enwerem JC, Nwanaji-Enwerem U, Baccarelli AA, Williams RF, Colicino E (2021) Anti-tumor necrosis factor drug responses and skin-blood DNA methylation age: relationships in moderate-to-severe psoriasis. Exp Dermatol 30:1197–1203. https://doi.org/10.1111/exd.14207
doi: 10.1111/exd.14207
pubmed: 33015854
Langley RG et al (2021) Reduced risk of mortality associated with systemic psoriasis treatment in the psoriasis longitudinal assessment and registry (PSOLAR): a nested case-control analysis. J Am Acad Dermatol 84:60–69. https://doi.org/10.1016/j.jaad.2020.08.032
doi: 10.1016/j.jaad.2020.08.032
pubmed: 32798580
Shen C et al (2018) DNA methylation age is not affected in psoriatic skin tissue. Clin Epigenetics 10:160. https://doi.org/10.1186/s13148-018-0584-y
doi: 10.1186/s13148-018-0584-y
pubmed: 30587242
pmcid: 6307188
Borsky P et al (2021) Aging in psoriasis vulgaris: female patients are epigenetically older than healthy controls. Immun Ageing 18:10. https://doi.org/10.1186/s12979-021-00220-5
doi: 10.1186/s12979-021-00220-5
pubmed: 33658053
pmcid: 7927262